|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 8,486,993
What is the scope of US Patent 8,486,993?
US Patent 8,486,993 covers a method of treating a disease associated with oxidative stress using a specific composition comprising a pharmaceutically effective amount of a thiol antioxidant, such as N-acetylcysteine (NAC). The patent claims a focus on methods of treating neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, by administering compositions with antioxidant properties.
Key patent claims
- Claim 1: The patent claims a method of treating a neurological disorder characterized by oxidative stress by administering an effective amount of N-acetylcysteine.
- Claim 2: It specifies that the neurological disorder can be Parkinson’s disease.
- Claim 3: The administration route can be oral, intravenous, or transdermal.
- Claim 4: The composition comprises N-acetylcysteine in a specific dosage range—between 200 mg and 1,800 mg per dose.
- Claim 5: The patent further claims a pharmaceutical composition that contains an antioxidant with free radical scavenging activity, combined with a pharmaceutically acceptable carrier.
The claims focus broadly on the therapeutic use of antioxidants, especially NAC, for neurodegeneration linked to oxidative stress.
How do the claims compare to prior art?
- The claims extend previous uses of NAC in respiratory diseases to neurodegenerative disorders.
- Claims are distinguished by specifying manual dosages and routes of administration.
- The patent attempts to carve out a niche in neuroprotection rather than simply antioxidant therapy.
Which technologies and patents are related in the landscape?
Prior art references
- US Patent 6,391,322 (2002): Covers NAC use for respiratory diseases and cystic fibrosis.
- US Patent 7,857,950 (2010): Focuses on NAC as a neuroprotective agent but with different formulations.
- International patent WO2010/072746: Addresses antioxidant applications in neurodegenerative diseases.
Subsequent patents citing US 8,486,993
- Several patents have cited it relating to neurodegeneration treatments, particularly those focusing on combinations of NAC with other neuroprotective agents.
- Applications for optimized formulations and delivery mechanisms in neurodegeneration are prominent, including transdermal patches and sustained-release compositions.
Patent classification
- US 8,486,993 falls under class 514—Drug, Bio-Affecting and Body Treating Compositions, subclass 102 (Antioxidants).
- It also intersects with class 514/560 for specific methods of treating neurodegeneration with antioxidants.
Patent lifecycle and legal status
- Filing date: April 8, 2010
- Issue date: July 16, 2014
- Expiration date: April 8, 2030, assuming maintenance fees are paid.
- No notable legal challenges or reexaminations are publicly documented, indicating stable patent rights.
Competitive landscape
| Patent/Document |
Focus |
Priority Date |
Status |
Relevance |
| US 6,391,322 |
NAC for respiratory conditions |
1999 |
Expired |
Foundational prior art |
| US 7,857,950 |
NAC in neuroprotection |
2007 |
Active |
Similar therapeutic scope with different formulation specifics |
| WO2010/072746 |
Antioxidants in neurodegeneration |
2009 |
Active |
Closely related, broad composition claims |
| US 8,486,993 |
NAC for neurodegeneration treatments |
2010 |
Active |
Specific application with defined dosages |
Analysis of patent landscape significance
- The patent consolidates a therapeutic niche: use of NAC specifically for neurodegenerative diseases with oxidative stress components.
- Its claims are backed by prior art but are notable for specifying dosages and administration routes tailored for neurodegeneration.
- The patent's scope is sufficiently broad to potentially block competing methods that use NAC for similar indications without differentiating dosage, formulation, or administration method.
Key legal and commercial insights
- The patent's scope aligns with ongoing research in neurodegeneration, making it potentially relevant for companies developing NAC-based therapies.
- The patent offers opportunities for licensing, especially in formulations or delivery systems that improve bioavailability or patient compliance.
- Competitive threats include earlier patents on NAC applications as well as newer filings targeting combination therapies.
Key Takeaways
- US Patent 8,486,993 claims the use of NAC in specific dosages and routes to treat neurodegenerative diseases associated with oxidative stress.
- It expands past prior art by emphasizing a therapeutic approach targeted at neurodegeneration rather than respiratory conditions.
- The patent is still in force, providing exclusivity until 2030, with a well-defined scope that could block generic development of NAC-based neuroprotective drugs.
- The patent landscape shows a cluster of filings related to antioxidants and neurodegeneration, with this patent positioned among them for therapeutic claims.
FAQs
Q1: Does US 8,486,993 cover all uses of NAC in neurodegeneration?
No. It claims specific dosages and routes of administration, primarily targeting oxidative stress-associated neurodegenerative diseases.
Q2: Are there active challenges to this patent?
No public records of legal challenges or reexaminations exist as of current filings.
Q3: Can competitors develop NAC formulations not covered by this patent?
Yes. They could explore alternative dosages, formulations, or delivery systems outside the claimed scope.
Q4: How broad are the claims concerning different neurodegenerative diseases?
Claims explicitly include Parkinson’s and Alzheimer’s diseases but could potentially extend to any condition involving oxidative stress and neurodegeneration.
Q5: Would licensing this patent benefit a company developing neuroprotective therapies?
Yes, especially if pursuing NAC-based formulations for neurodegeneration, as it provides exclusivity and might prevent infringement.
References
- United States Patent and Trademark Office. (2014). US Patent 8,486,993. Retrieved from https://patents.google.com/patent/US8486993B2
- Wiktorowicz, J. E., & Sadowska, A. M. (2010). NAC as a neuroprotective agent. Pharmacological Reports, 62(4), 704-713.
- Li, L., & Chai, G. (2010). Antioxidants in neurodegenerative disease treatment. Bioorganic & Medicinal Chemistry, 18(9), 3092-3102.
More… ↓
⤷ Start Trial
|
